Study #2020-1060
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
MD Anderson Study Status
Enrolling
Treatment Agent
RO7198457 intravenous (IV)
Description
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Study phase:
Phase II
Physician name:
Van Morris
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-642-1954
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.